In patients with type 2 diabetes on metformin, liraglutide 1.2 mg reduced HbA1c more than sitagliptin at 52 weeks (-1.29% versus -0.88%; difference -0.40%, 95% CI -0.59 to -0.22; p<0.0001).
In plain wordsIn people with type 2 diabetes on metformin, liraglutide 1.2 mg lowered HbA1c more than sitagliptin over 52 weeks.
- Peptide
- Liraglutide
- Outcome
- DecreaseHbA1c change from baseline to 52 weeks, liraglutide 1.2 mg
- Study
n: not reported in source
- Comparator
- Sitagliptin 100 mg/day
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- 1.2 mg/day · 52 weeksAs given in this study (human).
Source sentences
Liraglutide (1.2 or 1.8 mg) was superior to sitagliptin for reducing HbA(1c) from baseline (8.4-8.5%) to 52 weeks: -1.29% and -1.51% vs. -0.88% respectively.
2 context sentences(design, population, supporting numbers)
Estimated mean treatment differences between liraglutide and sitagliptin were as follows: -0.40% (95% confidence interval -0.59 to -0.22) for 1.2 mg and -0.63% (-0.81 to -0.44) for 1.8 mg (both p<0.0001).
In an open-label, parallel-group trial, metformin-treated participants were randomised to liraglutide 1.2 mg/day (n=225), liraglutide 1.8 mg/day (n=221) or sitagliptin 100 mg/day (n=219) for 26 weeks (main phase).